ASH 2010 - Orlando

Deininger

http://asheducationbook.hematologylibrary.org/cgi/content/full/2008/1/418

Monitoring disease response to tyrosine kinase inhibitor therapy in CML

Timothy P. Hughes and Susan Branford

Correspondence: Timothy P. Hughes, MD, Division of Haematology, SA Pathology, Frome Road, Adelaide, South Australia 5000, Australia; Phone: 61 (8) 82223330

http://asheducationbook.hematologylibrary.org/cgi/content/full/2009/1/47

Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance

Dale Bixby and Moshe Talpaz

Correspondence: Moshe Talpaz, MD, 1500 East Medical Center Drive, 4302 CCC/SPC 5936, Ann Arbor, MI 48109-5936

http://asheducationbook.hematologylibrary.org/cgi/content/full/2009/1/461

Initial treatment for patients with CML

John M. Goldman

Correspondence: John M. Goldman, DM, FRCP, FRCPath, Department of Hematology, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, United Kingdom

http://asheducationbook.hematologylibrary.org/cgi/content/full/2009/1/453

1199 Induction of CABLES1 by the TKI Inhibits the Cell Cycle Progression and Induces Apoptosis In CML Cell.....results demonstrated that the Bcr-Abl suppressed the expression of CABLES1, and the depletion of CABLES1 promotes cell cycle progression and p53-dependent apoptosis. Moreover, the induction of CABLES1 expression has the potentiality to eradicate CML stem/progenitor cells.

http://ash.confex.com/ash/2010/webprogram/Paper26449.html

356 Early Switching From Imatinib to Nilotinib In CML Patients Failing to Achieve Early Molecular Targets May Not Be An Effective Approach In Patients with Very Low OCT-1 Activity: A TIDEL II Sub-Study

This preliminary data suggests that patients with low OA may have more generalized insensitivity to kinase inhibitor therapy which is not simply related to drug transport. These are important findings in the setting of multiple TKIs being available, and suggest that in patients with very low OA a regimen of selective TKI intensification may not be the optimal approach.

http://ash.confex.com/ash/2010/webprogram/Paper30894.html 

Links to Abstracts:

http://ash.confex.com/ash/2010/webprogram/Session2872.html

http://ash.confex.com/ash/2010/webprogram/Session2779.html

1234- Analysis of Outcomes in Adolescents and Yound Adults (AYA) with CML Treated with Upfront TKI's- read conclusions- surprisingly AYA do not have as deep a response to therapy as older age groups suggesting that compliance or therapy adherence issues are at play.

http://ash.confex.com/ash/2010/webprogram/Paper33707.html